ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Intersect ENT, Inc.

Rowley Law PLLC is investigating potential securities law violations by Intersect ENT, Inc. (NASDAQ: XENT) and its board of directors concerning the proposed acquisition of the company by Medtronic plc (NYSE: MDT). Stockholders will receive $28.25 for each share of Intersect ENT stock that they hold. The transaction is valued at approximately $1.1 billion and is expected to close by April 2022 .

If you are a stockholder of Intersect ENT, Inc. and are interested in obtaining additional information regarding this investigation, please visit us at: https://www.rowleylawpllc.com/investigation/xent /. You may also contact Shane Rowley, Esq. at Rowley Law PLLC, 50 Main Street Suite 1000, White Plains, NY 10606, by email at info@rowleylawpllc.com , or by telephone at 914-400-1920 or 844-400-4643 (toll-free).

Rowley Law PLLC represents shareholders nationwide in class actions and derivative lawsuits in complex corporate litigation. For more information about the firm and its attorneys, please visit https://www.rowleylawpllc.com .

Attorney Advertising. Prior results do not guarantee a similar outcome.

Cision View original content: https://www.prnewswire.com/news-releases/alert-rowley-law-pllc-is-investigating-proposed-acquisition-of-intersect-ent-inc-301351224.html

SOURCE Rowley Law PLLC

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Seegnal (TSXV:SEGN)

Seegnal Presents Real-World Evidence on Reducing Fall Risk in Geriatric Patients at Caltcm Summit

Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Corporation"), a global leader in AI-enhanced prescription intelligence, today announced real-world clinical results demonstrating how medication governance may reduce fall-risk drivers in older adults -- a significant clinical and financial challenge... Keep Reading...
Scientists working in a modern medical research laboratory.

Pathways to Commercialising Biotech Innovations

In the medical technology industry, innovation is only the first step. While key to long-term success, innovation is only as good as a company’s commercialisation strategy. Once a technology has been developed and proven, the organisation must then embark on a process to commercialise it for... Keep Reading...
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at... Keep Reading...
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the... Keep Reading...
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries CommenceDownload the PDF here. Keep Reading...
Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities. The groundbreaking developments in antifungal treatments specifically targeting women's health issues... Keep Reading...

Interactive Chart

Latest Press Releases

Related News